AOD-9604 in Sgurgola — Fat Loss Peptide Research Guide
AOD-9604 research guide for Sgurgola. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Sgurgola searching for AOD-9604, the key fact to understand is that this compound is distributed via specialist online vendors. This global online supply model is actually an advantage for quality — top vendors differentiate through analytical documentation in ways no local retailer can match. What genuinely separates top AOD-9604 vendors is full COA coverage: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. What follows is a sourcing and quality evaluation guide built specifically around AOD-9604, covering everything a Sgurgola researcher needs before placing a first order.
AOD-9604: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Sgurgola researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
Sourcing Research-Grade AOD-9604
Before looking at individual vendors, establish a quality benchmark — so you can tell whether a COA is complete and credible. Mass spectrometry in the COA verifies that the main HPLC peak is actually AOD-9604 and not another compound with similar chromatographic behaviour — HPLC purity alone does not confirm what the compound actually is. For Sgurgola researchers evaluating new suppliers: a modest first purchase to test the product before placing larger orders is standard practice in the community. Store lyophilised AOD-9604 at −20°C until ready to use; reconstitute only the quantity required for your immediate research and keep the remainder frozen.
Order AOD-9604 — ships to Sgurgola
COA-verified · International tracking · Research grade
All use of AOD-9604 in Sgurgola or anywhere constitutes research use — this compound is not approved for human therapeutic use, and all handling should comply with standard research safety practices. Reconstitute AOD-9604 with bacteriostatic water at the concentration suited to your research design; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. The most significant preventable safety hazard in AOD-9604 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the specific protection against this risk. Researchers combining AOD-9604 with other compounds should review the available literature for documented interactions before proceeding with any multi-compound protocol.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
